Coughing up blood, or sudden kidney problems such as passing very little urine or visibly bloody urine, needs emergency care. Call 911 or go to an emergency department now.
The test comes in two layers, a staining pattern reported as c-ANCA or p-ANCA, and an antigen-specific antibody measurement for PR3 or MPO. Neither layer stands alone. It is read next to symptoms, kidney function, inflammation markers and, where possible, tissue biopsy.
ANCA stands for anti-neutrophil cytoplasmic antibodies, and the test looks for antibodies the immune system has made against proteins stored inside a person's own neutrophils.
Neutrophils are the most numerous white blood cells in circulation and the immune system's first responders to bacteria. Inside them sit small packets called granules, loaded with enzymes that break down microbes. Two of those enzymes matter here, proteinase 3 (PR3) and myeloperoxidase (MPO). Under normal conditions they stay locked inside the cell, out of reach of the immune system.
In ANCA-associated vasculitis, those enzymes end up displayed on the neutrophil surface, circulating antibodies bind to them, and the neutrophil is activated while it is still inside a small blood vessel, releasing its destructive contents into the vessel wall rather than into an infected tissue 1. The result is necrotizing inflammation of the smallest arteries, capillaries and venules, which is why the organs richest in small vessels, the kidneys and the lungs, are so often involved 1.
So the blood test is indirect. It does not look at a blood vessel and it does not measure damage. It detects the antibody that research suggests sits at the centre of how that damage happens 1. That distinction explains almost everything else about how the result is interpreted. An antibody can be present before obvious illness, can persist after illness settles, and can occasionally appear in people who never develop vasculitis at all.
The term covers a family of autoimmune small-vessel diseases rather than a single condition, grouped together because they share this antibody and a similar pattern of vessel injury 2.
It matters because it points toward a group of uncommon conditions that can damage the kidneys and lungs quickly, and because recognising them early changes the entire clinical path.
The conditions grouped under ANCA-associated vasculitis are granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis 2. They are multi-system diseases. Presentations described in clinical reviews include persistent sinus and nasal symptoms, hearing changes, cough and breathlessness, skin rashes, nerve symptoms in the hands or feet, joint pain, fever and unexplained weight loss, often building over weeks rather than hours 3.
The kidney involvement is the part that drives urgency. In these conditions the kidney filters can be attacked with very little antibody deposited in the tissue, a pattern described as pauci-immune necrotizing and crescentic glomerulonephritis, and it can progress fast enough to threaten kidney function 4. The lung involvement can take the form of bleeding into the air sacs, which is why coughing up blood is treated as an emergency rather than a symptom to monitor 3.
Because the early symptoms are so ordinary, people often cycle through several explanations before anyone orders this test. That is the practical reason the marker matters. It converts a vague, multi-organ picture into a specific question that can be answered, and European recommendations advise that care for these conditions is organised in, or in close collaboration with, centres of expertise 5.
They are two staining patterns, not two different antibodies, and they describe where the antibody lights up on a prepared slide of donor neutrophils under a fluorescence microscope.
In the indirect immunofluorescence method, serum is washed over fixed neutrophils. If antibodies bind, a fluorescent tag reveals the location. Diffuse staining across the body of the cell is reported as cytoplasmic, or c-ANCA. Staining concentrated around the nucleus is reported as perinuclear, or p-ANCA. A third category, atypical p-ANCA, describes patterns that do not fit either description cleanly.
The patterns are useful shorthand because each usually corresponds to a particular target antigen, but the correspondence is a tendency rather than a rule 2.
| Staining pattern | Usual target antigen | Typically reported in |
|---|---|---|
| c-ANCA (cytoplasmic) | PR3 (proteinase 3) | Granulomatosis with polyangiitis |
| p-ANCA (perinuclear) | MPO (myeloperoxidase) | Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis |
| Atypical p-ANCA | Neutrophil proteins other than PR3 or MPO | Inflammatory conditions outside primary vasculitis |
| Negative | No binding detected | Does not by itself exclude small-vessel vasculitis |
The perinuclear pattern is partly an artefact of how the slide is prepared. MPO is a positively charged protein, and the ethanol fixation used in the standard method lets it migrate toward the nucleus, producing the ring. That quirk is one reason the pattern alone was never enough and why antigen-specific testing became the anchor of the result 2.
MPO and PR3 are the two specific neutrophil enzymes that the clinically important antibodies target, and modern reporting leads with them rather than with the staining pattern.
MPO, or myeloperoxidase, is the enzyme neutrophils use to generate bleach-like oxidants during infection. PR3, or proteinase 3, is a protein-cutting enzyme from the same granules. An antigen-specific immunoassay coats a plate or bead with purified MPO or purified PR3 and measures how much antibody in the sample sticks to it, producing a number rather than a picture.
Research suggests that high-quality antigen-specific immunoassays for PR3 and MPO perform well enough to serve as the primary screening approach, rather than relying on immunofluorescence patterns alone 2. The antigen also carries clinical information beyond the label. Studies indicate that PR3-ANCA and MPO-ANCA disease differ in their typical organ patterns and in how they behave over time, which is why the antigen, not only the diagnosis, is recorded 1.
There is one more practical point worth knowing. MPO as an antibody target is not the same thing as an MPO activity measurement used in cardiovascular inflammation panels. Same enzyme, entirely different question. If a report mentions MPO, it is worth checking which of the two was run before reading anything into it.
It is a standard venous blood draw, usually from the arm, with the serum sent to a laboratory that runs an immunoassay, an immunofluorescence slide, or both.
No fasting is required and no special preparation is involved. The sample is spun to separate serum, then tested. Most laboratories now run the antigen-specific immunoassays for PR3 and MPO as the core test and add or reflex to immunofluorescence depending on their own protocol and the clinical question 2. Turnaround depends entirely on whether the assay runs in house or is sent to a reference laboratory, so the sensible move is to ask the ordering clinician when results are expected rather than assume a timeframe.
The more important question is when the test should be ordered at all. Reviews of diagnosis stress that this test performs best when there is a genuine clinical suspicion of small-vessel vasculitis, because ordering it broadly in low-suspicion situations raises the share of positive results that turn out not to reflect vasculitis 2. That is a property of every test, not a flaw in this one. The pre-test picture shapes what a positive result is worth.
In practice, the test rarely travels alone. It is usually ordered as part of a workup that includes kidney function, urinalysis, inflammation markers and a full blood count, because the vasculitis question is about organ involvement, not only antibodies 3.
Results arrive in two formats, a qualitative pattern and a numeric antibody level, and they answer slightly different questions.
| What the lab reports | Format | What it tells you |
|---|---|---|
| Immunofluorescence pattern | c-ANCA, p-ANCA, atypical, or negative | Where the antibody binds on prepared neutrophils |
| Immunofluorescence titre | A dilution ratio, reported where the method is used | How far the sample can be diluted and still show binding |
| PR3 antibody | A number in the assay's own units, with a positive or negative call | Whether antibody against proteinase 3 is detectable |
| MPO antibody | A number in the assay's own units, with a positive or negative call | Whether antibody against myeloperoxidase is detectable |
These are typical laboratory reporting formats. Cut-offs and units differ between assays and manufacturers, so a number from one laboratory cannot be compared directly with a number from another, and ranges vary by lab, age and sex.
There is no FitScript optimal range for this marker, and that is deliberate. An optimal range makes sense for a continuous marker where a target zone is meaningful. This is an autoantibody, so the clinically useful statement is detectable or not detectable against a validated cut-off, interpreted alongside the clinical picture.
One habit worth building. When comparing a result with an older one, check that both came from the same laboratory using the same assay. A changed number across two different methods may say more about the method than about the person.
A positive result means detectable antibody against PR3 or MPO, which raises the probability of ANCA-associated vasculitis in someone with matching clinical features, and means considerably less in someone without them.
Read it in three steps. The observation is that antibody against a specific neutrophil enzyme is present. The possible meaning is that the immune process behind small-vessel vasculitis is active, with the antigen hinting at which pattern of disease is more likely, since PR3 positivity is more often reported in granulomatosis with polyangiitis and MPO positivity in microscopic polyangiitis 2. The next step is a clinician-led assessment of whether any organ is actually involved, because the antibody describes a mechanism and the organ tests describe the consequences.
That is why a positive result usually triggers a search rather than a conclusion. Kidney function and urine sediment are examined for signs of glomerular inflammation, and imaging and lung assessment follow if there are respiratory symptoms 4. Where it is feasible and safe, tissue biopsy remains the step that confirms the pattern of vessel injury rather than inferring it 2.
No single value proves anything here. A positive antibody with abnormal urine sediment and declining kidney function is a very different situation from the same antibody in a person with normal organ tests and no symptoms. Both are worth discussing with a clinician promptly, but they lead to different conversations.
Less than most people assume. A negative result lowers the probability of ANCA-associated vasculitis but does not exclude it, which is why clinical judgment stays in charge.
There are two reasons. The first is biological. A minority of people with eosinophilic granulomatosis with polyangiitis test negative for these antibodies, and when they are positive the target is usually MPO, so a negative result there carries limited weight 2. Small-vessel vasculitis without detectable ANCA is recognised across the group as a whole 1.
The second is technical. Assays differ, cut-offs differ, and a value sitting just below a threshold is not meaningfully different from one sitting just above it. Laboratories set cut-offs to balance missed cases against false alarms, and no cut-off separates the two perfectly.
The practical consequence is simple. If symptoms suggestive of small-vessel disease continue, a negative antibody result is not a reason to stop looking. Kidney and lung involvement are identified through urine testing, kidney function and imaging, and tissue biopsy may be considered regardless of the antibody status 4. No one should be told to ignore ongoing symptoms because one antibody came back negative.
Yes. Detectable ANCA is reported in situations outside primary small-vessel vasculitis, which is one of the main reasons the result is never read in isolation.
The atypical perinuclear pattern in particular shows up in inflammatory conditions that are not vasculitis, and ANCA positivity is described in a range of chronic inflammatory and infectious settings, so the context of testing matters as much as the result itself 2. Certain medicines are also recognised causes of ANCA positivity, which is why a full medication and supplement history is part of the assessment, and why a licensed provider reviews that history rather than the reader interpreting it alone 2.
This is also where the distinction between the staining pattern and the antigen earns its keep. A perinuclear pattern with no detectable MPO or PR3 antibody points in a different direction from a perinuclear pattern with clearly positive MPO antibody. The first often reflects something other than ANCA-associated vasculitis, the second is far more specific 2.
None of this makes a positive result something to shrug off. It makes it a finding that needs context, and the context comes from symptoms, organ testing and a clinician who can see the whole picture.
C-Reactive Protein is a general inflammation marker, so it reflects how much inflammatory activity is present rather than what is driving it.
A typical lab reference range is 0 to 3 mg/L, and FitScript's optimal range is 0 to 1 mg/L. Optimal ranges are FitScript's optimization targets, not diagnostic cut-offs, and reference ranges vary by lab, age and sex. In a suspected small-vessel vasculitis workup, a raised value supports the impression that something inflammatory is active, while a value inside the range does not settle the question either way.
The full explanation of what the marker measures, how it is run and what moves it lives on the C-Reactive Protein page.
The antibody answers one question, so it is ordered alongside tests that show whether organs are affected and how much inflammation is present.
| Test | What it adds to the picture |
|---|---|
| ESR | A slower-moving general inflammation signal that complements CRP |
| Creatinine | Kidney filtration, the main way kidney involvement is tracked |
| Urinalysis with sediment | Blood, protein and red cell casts, the earliest sign of glomerular inflammation |
| Full blood count | Anaemia, platelet changes and eosinophil count |
| Chest imaging | Lung nodules, infiltrates or signs of bleeding into the air sacs |
Urinalysis deserves particular attention. Dysmorphic red blood cells and red cell casts point to inflammation inside the kidney filters themselves, and in this group of conditions that finding can appear before a person notices anything at all 4. It is cheap, fast and frequently the test that changes the urgency of everything else.
Broad baseline panels have a role here too, not as a substitute for targeted testing but as context. FitScript is built around repeat biomarker testing, with 150+ biomarkers tested per year and interpretation from Atlas, FitScript's AI health advisor, which means inflammation markers and kidney function have a history rather than a single data point. A creatinine value that has drifted upward over a year reads very differently from the same value seen once.
They are different antibodies looking for different disease families, even though both are autoantibody screens run on blood and both are often ordered during the same investigation.
ANA, or antinuclear antibody, detects antibodies against components of the cell nucleus and is used mainly when conditions such as lupus or connective tissue disease are being considered. ANCA detects antibodies against enzymes in neutrophil granules and is used when small-vessel vasculitis is being considered. The confusion is understandable, partly because the perinuclear ANCA pattern appears near the nucleus on a slide and a strongly positive ANA can interfere with reading an immunofluorescence slide at all. That interference is one more reason laboratories lean on antigen-specific assays for PR3 and MPO.
The interpretation habits differ as well. A positive ANA is common in the general population and frequently means nothing in isolation, whereas a clearly positive antigen-specific ANCA in a symptomatic person is a more pointed finding. If an ANA has come back positive and the meaning is unclear, the positive ana test guide walks through how that result is read.
Both tests share one rule. They describe immune activity, not organ damage, and neither replaces the examination and organ testing that follow.
The next phase is about mapping organ involvement and confirming the diagnosis, not about the antibody number.
Assessment typically covers kidney function and urine sediment, lung imaging and symptoms, ear, nose and throat involvement, skin, and nerve symptoms, because the extent of organ involvement determines how urgent the situation is 3. Where it can be done safely, biopsy of an affected organ confirms the pattern of small-vessel injury, and kidney biopsy also gives information about how much of the kidney is still viable 4.
Referral is part of the standard path rather than an escalation. European recommendations advise that people with these conditions are managed in, or in close collaboration with, centres of expertise, with a multidisciplinary approach and shared decision making 5. All treatment decisions belong to a licensed provider who has reviewed the person in front of them.
It is worth being direct about pace. When kidney function is changing or there is bleeding into the lungs, this is a situation where days matter, and it is worth discussing with a clinician promptly rather than waiting for a routine appointment. When the antibody is positive but organ tests are clean and symptoms are mild, the same assessment still happens, just without the same clock running.
Antibody levels can change over time, and they are often repeated during follow-up, but a change in the number is interpreted alongside clinical findings rather than acted on by itself.
Two findings shape how follow-up testing is used. First, the antigen carries prognostic information, and PR3-ANCA is associated with a higher risk of relapse than MPO-ANCA, which influences how closely someone is followed 6. Second, European recommendations advise structured, regular assessment of disease activity, organ function and damage during follow-up, with serial antibody measurement interpreted in that clinical context rather than as a standalone trigger 5.
In plain terms, a rising antibody level in someone who feels well and has normal urine and kidney tests is a reason for closer attention, not an automatic conclusion that disease has returned. A rising level alongside new symptoms, new blood in the urine or a change in kidney function is a different signal entirely.
This is also where general markers earn their place. Inflammation markers and kidney function are followed over time because they reflect what is happening in tissue, and long-term kidney outcomes are a central concern in these conditions 6. A trend across several results tells a clearer story than any single reading.
Any positive result, and any set of symptoms suggesting small-vessel involvement, is worth a clinician's review, and some situations should not wait.
Coughing up blood, sudden breathlessness, passing very little urine or visibly bloody urine are emergency presentations. Call 911 or go to an emergency department. Do not wait for a repeat blood test.
Book a prompt appointment, rather than an emergency visit, for symptoms that persist without explanation, including unrelenting sinus congestion or crusting, nosebleeds, hearing change, a cough that will not clear, fever and weight loss without a cause, new numbness or weakness in a hand or foot, or a rash of small raised purple spots on the legs. Individually these are common and usually harmless. In combination, and lasting weeks, they are the pattern described in clinical reviews of this group of conditions 3.
Bring the full report to that appointment, not just the positive or negative line. The antigen tested, the assay units and the laboratory that ran it all matter for interpretation. Discuss your results, and any next step, with a clinician or licensed provider who can see your history, your examination and your other tests. This page is educational and not medical advice.
It means the laboratory detected antibodies against PR3 or MPO, two enzymes found inside neutrophils. On its own it is not a diagnosis. Its weight depends on symptoms and on what kidney function, urine testing and imaging show, and a clinician puts those pieces together.
No. ANA looks for antibodies against parts of the cell nucleus and is used when conditions such as lupus are being considered. ANCA looks for antibodies against enzymes inside neutrophils and is used when small-vessel vasculitis is being considered. They are sometimes ordered together, but they answer different questions.
No. It is a standard venous blood draw with no fasting and no special preparation. If other tests are being drawn at the same visit, one of those may require fasting, so check the instructions for the whole order rather than this test alone.
They describe where the antibody lights up on a prepared slide of neutrophils. Cytoplasmic staining is reported as c-ANCA and usually corresponds to PR3, while perinuclear staining is reported as p-ANCA and usually corresponds to MPO. Most laboratories now lead with the specific PR3 and MPO antibody measurements.
Yes. Detectable ANCA turns up in some other inflammatory and infectious conditions, and certain medicines are recognised causes of a positive result. This is why a clinician reviews the full history, including every medicine and supplement, before drawing any conclusion from the result.
Yes, which is why a negative result is never treated as the end of an investigation. If symptoms suggesting small-vessel involvement continue, urine testing, kidney function, imaging and sometimes a tissue biopsy are still used. Never ignore ongoing symptoms because one antibody test came back negative.
That depends on the person, and a clinician sets the schedule. The antibody level is generally followed alongside symptoms, urine testing and kidney function rather than on its own, because a changed number means different things depending on how someone is doing clinically.
Commonly kidney function including creatinine, urinalysis with sediment examination, inflammation markers such as CRP and ESR, and a full blood count. Chest imaging is often added when there are respiratory symptoms. These tests show whether organs are involved, which the antibody result alone cannot tell you.